Long-Term Oxygen Therapy — SCE Respiratory MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Idiopathic, heritable and drug-associated pulmonary arterial hypertension
Acute vasoreactivity testing for selection of high-dose calcium-channel-blocker treatment is confined to idiopathic, heritable or drug-associated pulmonary arterial hypertension. It is not recommended for other PAH associations or for groups 2, 3 or 4 because a positive acute response does not identify a group with established durable benefit and treatment may cause harm.
Reference: 2022 ESC and ERS guideline for pulmonary hypertension (Published 2022): https://academic.oup.com/eurheartj/article/43/38/3618/6673929; 2022 ESC and ERS pulmonary-hypertension guideline in the European Respiratory Journal (Published 2022): https://publications.ersnet.org/content/erj/61/1/2200879